Lanreotide Injection — Class II drug recall D-0290-2026
Ongoing recall by Cipla USA, Inc., reported 2026-01-21, distributed nationwide. Presence of Particulate Matter.
| Recall number | D-0290-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Cipla USA, Inc., Warren, NJ, United States |
| Recall initiated | 2026-01-02 |
| Classified | 2026-01-15 |
| Reported by FDA | 2026-01-21 |
| Distributed | Nationwide (US) |
| Quantity | 15,221 syringes |
| Reason classes | specification failure |
| NDC | 69097-0870, 69097-0870-67, 69097-0880, 69097-0880-67, 69097-0890, 69097-0890-67 |
| Lot numbers | 4301954IR1, 4301994IR1, 4301995IR1, 4301996IR1, 4400005IR1, 4400006IR1, 4400007IR1, 4400124IR1, 4400154IR1, 4400155IR1, 4400156IR1, 4400373IR1, 4400374IR1, 4400375IR1, 4400455IR1, 4400456IR1, 4400457IR1, 4400544IR1, 4400606IR1, 4400607IR1, 4400696IR1, 4400697IR1, 4400779IR1, 4400780IR1, 4400781IR1, 4400844IR1, 4400845IR1, 4400849IR1, 4400984IR1, 4400985RIR, 4400986IR1, 4401023IR1 |
Product
Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67
Reason for recall
Presence of Particulate Matter.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0290-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.